{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T05:58:19Z","timestamp":1787637499799,"version":"build-2736575974"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T00:00:00Z","timestamp":1681084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T00:00:00Z","timestamp":1681084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Growing evidence has demonstrated that DNA methylation (DNAm) plays an important role in Alzheimer\u2019s disease (AD) and that DNAm differences can be detected in the blood of AD subjects. Most studies have correlated blood DNAm with the clinical diagnosis of AD in living individuals. However, as the pathophysiological process of AD can begin many years before the onset of clinical symptoms, there is often disagreement between neuropathology in the brain and clinical phenotypes. Therefore, blood DNAm associated with AD neuropathology, rather than with clinical data, would provide more relevant information on AD pathogenesis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We performed a comprehensive analysis to identify blood DNAm associated with cerebrospinal fluid (CSF) pathological biomarkers for AD. Our study included matched samples of whole blood DNA methylation, CSF A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      , phosphorylated tau\n                      <jats:sub>181<\/jats:sub>\n                      (pTau\n                      <jats:sub>181<\/jats:sub>\n                      ), and total tau (tTau) biomarkers data, measured on the same subjects and at the same clinical visits from a total of 202 subjects (123 CN or cognitively normal, 79 AD) in the Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI) cohort. To validate our findings, we also examined the association between premortem blood DNAm and postmortem brain neuropathology measured on a group of 69 subjects in the London dataset.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified a number of novel associations between blood DNAm and CSF biomarkers, demonstrating that changes in pathological processes in the CSF are reflected in the blood epigenome. Overall, the CSF biomarker-associated DNAm is relatively distinct in CN and AD subjects, highlighting the importance of analyzing omics data measured on cognitively normal subjects (which includes preclinical AD subjects) to identify diagnostic biomarkers, and considering disease stages in the development and testing of AD treatment strategies. Moreover, our analysis revealed biological processes associated with early brain impairment relevant to AD are marked by DNAm in the blood, and blood DNAm at several CpGs in the DMR on\n                      <jats:italic>HOXA5<\/jats:italic>\n                      gene are associated with pTau\n                      <jats:sub>181<\/jats:sub>\n                      in the CSF, as well as tau-pathology and DNAm in the brain, nominating DNAm at this locus as a promising candidate AD biomarker.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study provides a valuable resource for future mechanistic and biomarker studies of DNAm in AD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-023-01216-7","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T08:03:04Z","timestamp":1681113784000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Distinct CSF biomarker-associated DNA methylation in Alzheimer\u2019s disease and cognitively normal subjects"],"prefix":"10.1186","volume":"15","author":[{"given":"Wei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan I.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lissette","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lukacsovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achintya","family":"Varma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X. Steven","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eden R.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,10]]},"reference":[{"key":"1216_CR1","doi-asserted-by":"crossref","unstructured":"Rajan KB, et al. Population estimate of people with clinical Alzheimer\u2019s disease and mild cognitive impairment in the United States (2020\u20132060). Alzheimer\u2019s\u00a0Dement. 2021;17(12):1966\u201375.","DOI":"10.1002\/alz.12362"},{"key":"1216_CR2","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1056\/NEJMsa1204629","volume":"368","author":"MD Hurd","year":"2013","unstructured":"Hurd MD, Martorell P, Delavande A, Mullen KJ, Langa KM. Monetary costs of dementia in the United States. N Engl J Med. 2013;368:1326\u201334.","journal-title":"N Engl J Med"},{"key":"1216_CR3","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/nn.3792","volume":"17","author":"J Lord","year":"2014","unstructured":"Lord J, Cruchaga C. The epigenetic landscape of Alzheimer\u2019s disease. Nat Neurosci. 2014;17:1138\u201340.","journal-title":"Nat Neurosci"},{"key":"1216_CR4","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00401-016-1612-7","volume":"132","author":"HU Klein","year":"2016","unstructured":"Klein HU, Bennett DA, De Jager PL. The epigenome in Alzheimer\u2019s disease: current state and approaches for a new path to gene discovery and understanding disease mechanism. Acta Neuropathol. 2016;132:503\u201314.","journal-title":"Acta Neuropathol"},{"key":"1216_CR5","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2217\/nmt-2018-0004","volume":"8","author":"A Stoccoro","year":"2018","unstructured":"Stoccoro A, Coppede F. Role of epigenetics in Alzheimer\u2019s disease pathogenesis. Neurodegener Dis Manag. 2018;8:181\u201393.","journal-title":"Neurodegener Dis Manag"},{"key":"1216_CR6","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1038\/nn.3786","volume":"17","author":"PL De Jager","year":"2014","unstructured":"De Jager PL, et al. Alzheimer\u2019s disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci. Nat Neurosci. 2014;17:1156\u201363.","journal-title":"Nat Neurosci"},{"key":"1216_CR7","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1038\/nn.3782","volume":"17","author":"K Lunnon","year":"2014","unstructured":"Lunnon K, et al. Methylomic profiling implicates cortical deregulation of ANK1 in Alzheimer\u2019s disease. Nat Neurosci. 2014;17:1164\u201370.","journal-title":"Nat Neurosci"},{"key":"1216_CR8","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.jalz.2018.01.017","volume":"14","author":"RG Smith","year":"2018","unstructured":"Smith RG, et al. Elevated DNA methylation across a 48-kb region spanning the HOXA gene cluster is associated with Alzheimer\u2019s disease neuropathology. Alzheimers Dement. 2018;14:1580\u20138.","journal-title":"Alzheimers Dement"},{"key":"1216_CR9","doi-asserted-by":"publisher","first-page":"6114","DOI":"10.1038\/s41467-020-19791-w","volume":"11","author":"L Zhang","year":"2020","unstructured":"Zhang L, et al. Epigenome-wide meta-analysis of DNA methylation differences in prefrontal cortex implicates the immune processes in Alzheimer\u2019s disease. Nat Commun. 2020;11:6114.","journal-title":"Nat Commun"},{"key":"1216_CR10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s40478-021-01177-8","volume":"9","author":"L Zhang","year":"2021","unstructured":"Zhang L, et al. Sex-specific DNA methylation differences in Alzheimer\u2019s disease pathology. Acta Neuropathol Commun. 2021;9:77.","journal-title":"Acta Neuropathol Commun"},{"key":"1216_CR11","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.2217\/epi-2020-0236","volume":"12","author":"PD Fransquet","year":"2020","unstructured":"Fransquet PD, et al. DNA methylation analysis of candidate genes associated with dementia in peripheral blood. Epigenomics. 2020;12:2109\u201323.","journal-title":"Epigenomics"},{"key":"1216_CR12","first-page":"e12056","volume":"12","author":"P.D Fransquet","year":"2020","unstructured":"Fransquet P.D, et al. Blood DNA methylation signatures to detect dementia prior to overt clinical symptoms. Alzheimers Dement (Amst). 2020;12:e12056.","journal-title":"Alzheimers Dement (Amst)"},{"key":"1216_CR13","doi-asserted-by":"publisher","first-page":"12217","DOI":"10.1038\/s41598-020-69248-9","volume":"10","author":"N Kobayashi","year":"2020","unstructured":"Kobayashi N, et al. Increased blood COASY DNA methylation levels a potential biomarker for early pathology of Alzheimer\u2019s disease. Sci Rep. 2020;10:12217.","journal-title":"Sci Rep"},{"key":"1216_CR14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.neurobiolaging.2020.06.023","volume":"95","author":"JAY Roubroeks","year":"2020","unstructured":"Roubroeks JAY, et al. An epigenome-wide association study of Alzheimer\u2019s disease blood highlights robust DNA hypermethylation in the HOXB6 gene. Neurobiol Aging. 2020;95:26\u201345.","journal-title":"Neurobiol Aging"},{"key":"1216_CR15","doi-asserted-by":"publisher","first-page":"927","DOI":"10.3233\/JAD-180592","volume":"66","author":"A Madrid","year":"2018","unstructured":"Madrid A, et al. DNA hypomethylation in blood links B3GALT4 and ZADH2 to Alzheimer\u2019s disease. J Alzheimers Dis. 2018;66:927\u201334.","journal-title":"J Alzheimers Dis"},{"key":"1216_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0239196","volume":"15","author":"R Mitsumori","year":"2020","unstructured":"Mitsumori R, et al. Lower DNA methylation levels in CpG island shores of CR1, CLU, and PICALM in the blood of Japanese Alzheimer\u2019s disease patients. PLoS ONE. 2020;15: e0239196.","journal-title":"PLoS ONE"},{"key":"1216_CR17","doi-asserted-by":"publisher","first-page":"4852","DOI":"10.1038\/s41467-022-32475-x","volume":"13","author":"T, C.S","year":"2022","unstructured":"Silva, TC, et al. Cross-tissue analysis of blood and brain epigenome-wide association studies in Alzheimer\u2019s disease. Nat Commun. 2022;13:4852.","journal-title":"Nat Commun"},{"key":"1216_CR18","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","volume":"9","author":"CR Jack Jr","year":"2010","unstructured":"Jack CR Jr, et al. Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade. Lancet Neurol. 2010;9:119\u201328.","journal-title":"Lancet Neurol"},{"key":"1216_CR19","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:280\u201392.","journal-title":"Alzheimers Dement"},{"key":"1216_CR20","doi-asserted-by":"crossref","unstructured":"Jansen WJ, Janssen O, Tijms BM, et al. Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurol. 2022;79(3): 228\u201343.","DOI":"10.1001\/jamaneurol.2021.5216"},{"key":"1216_CR21","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1001\/jama.2015.4669","volume":"313","author":"R Ossenkoppele","year":"2015","unstructured":"Ossenkoppele R, et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA. 2015;313:1939\u201349.","journal-title":"JAMA"},{"key":"1216_CR22","doi-asserted-by":"publisher","first-page":"e0182098","DOI":"10.1371\/journal.pone.0182098","volume":"12","author":"D.A Llano","year":"2017","unstructured":"Llano D.A, Bundela S, Mudar R.A, Devanarayan V, Alzheimer\u2019s Disease Neuroimaging, I. A multivariate predictive modeling approach reveals a novel CSF peptide signature for both Alzheimer\u2019s Disease state classification and for predicting future disease progression. PLoS One. 2017;12:e0182098.","journal-title":"PLoS One"},{"key":"1216_CR23","doi-asserted-by":"publisher","first-page":"19024","DOI":"10.1038\/s41598-019-54204-z","volume":"9","author":"K Blennow","year":"2019","unstructured":"Blennow K, et al. Predicting clinical decline and conversion to Alzheimer\u2019s disease or dementia using novel Elecsys Abeta(1\u201342), pTau and tTau CSF immunoassays. Sci Rep. 2019;9:19024.","journal-title":"Sci Rep"},{"key":"1216_CR24","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1001\/archneur.60.12.1696","volume":"60","author":"CM Clark","year":"2003","unstructured":"Clark CM, et al. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol. 2003;60:1696\u2013702.","journal-title":"Arch Neurol"},{"key":"1216_CR25","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ana.21610","volume":"65","author":"LM Shaw","year":"2009","unstructured":"Shaw LM, et al. Cerebrospinal fluid biomarker signature in Alzheimer\u2019s disease neuroimaging initiative subjects. Ann Neurol. 2009;65:403\u201313.","journal-title":"Ann Neurol"},{"key":"1216_CR26","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1212\/01.WNL.0000046581.81650.D0","volume":"60","author":"D Strozyk","year":"2003","unstructured":"Strozyk D, Blennow K, White LR, Launer LJ. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology. 2003;60:652\u20136.","journal-title":"Neurology"},{"key":"1216_CR27","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1001\/archneurol.2008.596","volume":"66","author":"T Tapiola","year":"2009","unstructured":"Tapiola T, et al. Cerebrospinal fluid beta-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol. 2009;66:382\u20139.","journal-title":"Arch Neurol"},{"key":"1216_CR28","doi-asserted-by":"crossref","unstructured":"Grothe MJ, et al. Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy. Neurology. 2021;97(12):e1229\u201342.","DOI":"10.1212\/WNL.0000000000012513"},{"key":"1216_CR29","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14:535\u201362.","journal-title":"Alzheimers Dement"},{"key":"1216_CR30","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","volume":"87","author":"CR Jack Jr","year":"2016","unstructured":"Jack CR Jr, et al. A\/T\/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87:539\u201347.","journal-title":"Neurology"},{"key":"1216_CR31","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jalz.2018.08.005","volume":"15","author":"DP Veitch","year":"2019","unstructured":"Veitch DP, et al. Understanding disease progression and improving Alzheimer\u2019s disease clinical trials: recent highlights from the Alzheimer\u2019s Disease Neuroimaging Initiative. Alzheimers Dement. 2019;15:106\u201352.","journal-title":"Alzheimers Dement"},{"key":"1216_CR32","doi-asserted-by":"publisher","first-page":"203","DOI":"10.4161\/epi.23470","volume":"8","author":"YA Chen","year":"2013","unstructured":"Chen YA, et al. Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray. Epigenetics. 2013;8:203\u20139.","journal-title":"Epigenetics"},{"key":"1216_CR33","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1080\/15592294.2015.1057384","volume":"10","author":"T Wang","year":"2015","unstructured":"Wang T, et al. A systematic study of normalization methods for Infinium 450K methylation data using whole-genome bisulfite sequencing data. Epigenetics. 2015;10:662\u20139.","journal-title":"Epigenetics"},{"key":"1216_CR34","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/bioinformatics\/bts680","volume":"29","author":"AE Teschendorff","year":"2013","unstructured":"Teschendorff AE, et al. A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data. Bioinformatics. 2013;29:189\u201396.","journal-title":"Bioinformatics"},{"key":"1216_CR35","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12859-017-1511-5","volume":"18","author":"AE Teschendorff","year":"2017","unstructured":"Teschendorff AE, Breeze CE, Zheng SC, Beck S. A comparison of reference-based algorithms for correcting cell-type heterogeneity in Epigenome-Wide Association Studies. BMC Bioinformatics. 2017;18:105.","journal-title":"BMC Bioinformatics"},{"key":"1216_CR36","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13059-021-02275-5","volume":"22","author":"MF Nabais","year":"2021","unstructured":"Nabais MF, et al. Meta-analysis of genome-wide DNA methylation identifies shared associations across neurodegenerative disorders. Genome Biol. 2021;22:90.","journal-title":"Genome Biol"},{"key":"1216_CR37","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13148-020-00864-y","volume":"12","author":"A Vasanthakumar","year":"2020","unstructured":"Vasanthakumar A, et al. Harnessing peripheral DNA methylation differences in the Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI) to reveal novel biomarkers of disease. Clin Epigenetics. 2020;12:84.","journal-title":"Clin Epigenetics"},{"key":"1216_CR38","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00401-017-1685-y","volume":"133","author":"Y Deming","year":"2017","unstructured":"Deming Y, et al. Genome-wide association study identifies four novel loci associated with Alzheimer\u2019s endophenotypes and disease modifiers. Acta Neuropathol. 2017;133:839\u201356.","journal-title":"Acta Neuropathol"},{"key":"1216_CR39","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s00401-018-1881-4","volume":"136","author":"Y Deming","year":"2018","unstructured":"Deming Y, et al. Sex-specific genetic predictors of Alzheimer\u2019s disease biomarkers. Acta Neuropathol. 2018;136:857\u201372.","journal-title":"Acta Neuropathol"},{"key":"1216_CR40","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1111\/j.0006-341X.1999.00997.x","volume":"55","author":"B Delvin","year":"1999","unstructured":"Delvin B, Roeder K. Genomic control for association studies. Biometrics. 1999;55:997\u20131004.","journal-title":"Biometrics"},{"key":"1216_CR41","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13059-016-1131-9","volume":"18","author":"van Iterson, M., van Zwet, E.W., Consortium, B. & Heijmans, B.T","year":"2017","unstructured":"van Iterson, M., van Zwet, E.W., Consortium, B. & Heijmans, B.T. Controlling bias and inflation in epigenome- and transcriptome-wide association studies using the empirical null distribution. Genome Biol. 2017;18:19.","journal-title":"Genome Biol"},{"key":"1216_CR42","doi-asserted-by":"publisher","DOI":"10.1101\/2022.04.11.22273748","volume-title":"Cross-tissue meta-analysis of blood and brain epigenome-wide association studies in Alzheimer\u2019s disease","author":"TC Silva","year":"2022","unstructured":"Silva TC, et al. Cross-tissue meta-analysis of blood and brain epigenome-wide association studies in Alzheimer\u2019s disease. Nature Communications: In Press; 2022."},{"key":"1216_CR43","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3389\/fnagi.2017.00413","volume":"9","author":"A Starnawska","year":"2017","unstructured":"Starnawska A, et al. Epigenome-wide association study of cognitive functioning in middle-aged monozygotic twins. Front Aging Neurosci. 2017;9:413.","journal-title":"Front Aging Neurosci"},{"key":"1216_CR44","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1093\/bioinformatics\/bts545","volume":"28","author":"BS Pedersen","year":"2012","unstructured":"Pedersen BS, Schwartz DA, Yang IV, Kechris KJ. Comb-p: software for combining, analyzing, grouping and correcting spatially correlated P-values. Bioinformatics. 2012;28:2986\u20138.","journal-title":"Bioinformatics"},{"key":"1216_CR45","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1093\/bib\/bby085","volume":"20","author":"S Mallik","year":"2019","unstructured":"Mallik S, et al. An evaluation of supervised methods for identifying differentially methylated regions in Illumina methylation arrays. Brief Bioinform. 2019;20:2224\u201335.","journal-title":"Brief Bioinform"},{"key":"1216_CR46","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nbt.1630","volume":"28","author":"CY McLean","year":"2010","unstructured":"McLean CY, et al. GREAT improves functional interpretation of cis-regulatory regions. Nat Biotechnol. 2010;28:495\u2013501.","journal-title":"Nat Biotechnol"},{"key":"1216_CR47","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41586-021-03446-x","volume":"593","author":"J Nasser","year":"2021","unstructured":"Nasser J, et al. Genome-wide enhancer maps link risk variants to disease genes. Nature. 2021;593:238\u201343.","journal-title":"Nature"},{"key":"1216_CR48","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1093\/bioinformatics\/bty892","volume":"35","author":"X Ren","year":"2019","unstructured":"Ren X, Kuan PF. methylGSA: a Bioconductor package and Shiny app for DNA methylation data length bias adjustment in gene set testing. Bioinformatics. 2019;35:1958\u20139.","journal-title":"Bioinformatics"},{"key":"1216_CR49","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1216_CR50","doi-asserted-by":"publisher","first-page":"D109","DOI":"10.1093\/nar\/gkr988","volume":"40","author":"M Kanehisa","year":"2012","unstructured":"Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M. KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res. 2012;40:D109\u201314.","journal-title":"Nucleic Acids Res"},{"key":"1216_CR51","doi-asserted-by":"publisher","first-page":"D687","DOI":"10.1093\/nar\/gkab1028","volume":"50","author":"M Gillespie","year":"2022","unstructured":"Gillespie M, et al. The reactome pathway knowledgebase 2022. Nucleic Acids Res. 2022;50:D687\u201392.","journal-title":"Nucleic Acids Res"},{"key":"1216_CR52","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","volume":"18","author":"D Aran","year":"2017","unstructured":"Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18:220.","journal-title":"Genome Biol"},{"key":"1216_CR53","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/s41588-021-00923-x","volume":"53","author":"JL Min","year":"2021","unstructured":"Min JL, et al. Genomic and phenotypic insights from an atlas of genetic effects on DNA methylation. Nat Genet. 2021;53:1311\u201321.","journal-title":"Nat Genet"},{"key":"1216_CR54","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41588-019-0358-2","volume":"51","author":"BW Kunkle","year":"2019","unstructured":"Kunkle BW, et al. Genetic meta-analysis of diagnosed Alzheimer\u2019s disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. Nat Genet. 2019;51:414\u201330.","journal-title":"Nat Genet"},{"key":"1216_CR55","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13059-018-1448-7","volume":"19","author":"LA Salas","year":"2018","unstructured":"Salas LA, et al. An optimized library for reference-based deconvolution of whole-blood biospecimens assayed using the Illumina HumanMethylationEPIC BeadArray. Genome Biol. 2018;19:64.","journal-title":"Genome Biol"},{"key":"1216_CR56","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1080\/15592294.2015.1100786","volume":"10","author":"E Hannon","year":"2015","unstructured":"Hannon E, Lunnon K, Schalkwyk L, Mill J. Interindividual methylomic variation across blood, cortex, and cerebellum: implications for epigenetic studies of neurological and neuropsychiatric phenotypes. Epigenetics. 2015;10:1024\u201332.","journal-title":"Epigenetics"},{"key":"1216_CR57","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0197-4580(95)00021-6","volume":"16","author":"H Braak","year":"1995","unstructured":"Braak H, Braak E. Staging of Alzheimer\u2019s disease-related neurofibrillary changes. Neurobiol Aging. 1995;16:271\u20138 discussion 278\u201384.","journal-title":"Neurobiol Aging"},{"key":"1216_CR58","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0092-8674(88)80030-8","volume":"52","author":"S Mukherjee","year":"1988","unstructured":"Mukherjee S, Erickson H, Bastia D. Enhancer-origin interaction in plasmid R6K involves a DNA loop mediated by initiator protein. Cell. 1988;52:375\u201383.","journal-title":"Cell"},{"key":"1216_CR59","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.neuint.2015.01.008","volume":"82","author":"A.P Mazzetti","year":"2015","unstructured":"Mazzetti A.P, Fiorile M.C, Primavera A, Lo Bello M. Glutathione transferases and neurodegenerative diseases. Neurochem Int. 2015;82:10\u20138.","journal-title":"Neurochem Int"},{"key":"1216_CR60","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1080\/13543776.2017.1254192","volume":"27","author":"A Kumar","year":"2017","unstructured":"Kumar A, et al. Role of Glutathione-S-transferases in neurological problems. Expert Opin Ther Pat. 2017;27:299\u2013309.","journal-title":"Expert Opin Ther Pat"},{"key":"1216_CR61","doi-asserted-by":"publisher","first-page":"4865","DOI":"10.1038\/s41598-021-83872-z","volume":"11","author":"B Guennewig","year":"2021","unstructured":"Guennewig B, et al. Defining early changes in Alzheimer\u2019s disease from RNA sequencing of brain regions differentially affected by pathology. Sci Rep. 2021;11:4865.","journal-title":"Sci Rep"},{"key":"1216_CR62","doi-asserted-by":"publisher","first-page":"9613090","DOI":"10.1155\/2019\/9613090","volume":"2019","author":"A Nandi","year":"2019","unstructured":"Nandi A, Yan LJ, Jana CK, Das N. Role of catalase in oxidative stress- and age-associated degenerative diseases. Oxid Med Cell Longev. 2019;2019:9613090.","journal-title":"Oxid Med Cell Longev"},{"key":"1216_CR63","doi-asserted-by":"publisher","first-page":"38933","DOI":"10.1074\/jbc.M110.132860","volume":"285","author":"LK Habib","year":"2010","unstructured":"Habib LK, Lee MT, Yang J. Inhibitors of catalase-amyloid interactions protect cells from beta-amyloid-induced oxidative stress and toxicity. J Biol Chem. 2010;285:38933\u201343.","journal-title":"J Biol Chem"},{"key":"1216_CR64","doi-asserted-by":"publisher","first-page":"489","DOI":"10.2174\/138920212802510448","volume":"13","author":"X Lowe","year":"2012","unstructured":"Lowe X, Wyrobek A. Characterization of the early CNS stress biomarkers and profiles associated with neuropsychiatric diseases. Curr Genomics. 2012;13:489\u201397.","journal-title":"Curr Genomics"},{"key":"1216_CR65","doi-asserted-by":"publisher","first-page":"117693511982877","DOI":"10.1177\/1176935119828776","volume":"18","author":"JC Spainhour","year":"2019","unstructured":"Spainhour JC, Lim HS, Yi SV, Qiu P. Correlation patterns between DNA methylation and gene expression in The Cancer Genome Atlas. Cancer Inform. 2019;18:1176935119828776.","journal-title":"Cancer Inform"},{"key":"1216_CR66","doi-asserted-by":"publisher","first-page":"23882","DOI":"10.1074\/jbc.M114.573469","volume":"289","author":"K Bahar Halpern","year":"2014","unstructured":"Bahar Halpern K, Vana T, Walker M.D. Paradoxical role of DNA methylation in activation of FoxA2 gene expression during endoderm development. J Biol Chem. 2014;289:23882\u201392.","journal-title":"J Biol Chem"},{"key":"1216_CR67","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1471-2199-8-20","volume":"8","author":"B Hantusch","year":"2007","unstructured":"Hantusch B, Kalt R, Krieger S, Puri C, Kerjaschki D. Sp1\/Sp3 and DNA-methylation contribute to basal transcriptional activation of human podoplanin in MG63 versus Saos-2 osteoblastic cells. BMC Mol Biol. 2007;8:20.","journal-title":"BMC Mol Biol"},{"key":"1216_CR68","doi-asserted-by":"publisher","first-page":"38914","DOI":"10.1074\/jbc.M504633200","volume":"280","author":"MI Niesen","year":"2005","unstructured":"Niesen MI, et al. Activation of a methylated promoter mediated by a sequence-specific DNA-binding protein. RFX J Biol Chem. 2005;280:38914\u201322.","journal-title":"RFX J Biol Chem"},{"key":"1216_CR69","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nrg.2016.83","volume":"17","author":"H Zhu","year":"2016","unstructured":"Zhu H, Wang G, Qian J. Transcription factors as readers and effectors of DNA methylation. Nat Rev Genet. 2016;17:551\u201365.","journal-title":"Nat Rev Genet"},{"key":"1216_CR70","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1042\/EBC20190033","volume":"63","author":"E Heberle","year":"2019","unstructured":"Heberle E, Bardet AF. Sensitivity of transcription factors to DNA methylation. Essays Biochem. 2019;63:727\u201341.","journal-title":"Essays Biochem"},{"key":"1216_CR71","doi-asserted-by":"crossref","unstructured":"Yin Y, et al. Impact of cytosine methylation on DNA binding specificities of human transcription factors. Science. 2017;356(6337):eaaj2239.","DOI":"10.1126\/science.aaj2239"},{"key":"1216_CR72","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.00726","volume":"2","author":"S Hu","year":"2013","unstructured":"Hu S, et al. DNA methylation presents distinct binding sites for human transcription factors. Elife. 2013;2: e00726.","journal-title":"Elife"},{"key":"1216_CR73","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1093\/nar\/gkac030","volume":"50","author":"TC Silva","year":"2022","unstructured":"Silva TC, Young JI, Martin ER, Chen XS, Wang L. MethReg: estimating the regulatory potential of DNA methylation in gene transcription. Nucleic Acids Res. 2022;50:e51\u2013e51.","journal-title":"Nucleic Acids Res"},{"key":"1216_CR74","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/ng.3721","volume":"49","author":"MJ Bonder","year":"2017","unstructured":"Bonder MJ, et al. Disease variants alter transcription factor levels and methylation of their binding sites. Nat Genet. 2017;49:131\u20138.","journal-title":"Nat Genet"},{"key":"1216_CR75","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1004663","volume":"10","author":"NE Banovich","year":"2014","unstructured":"Banovich NE, et al. Methylation QTLs are associated with coordinated changes in transcription factor binding, histone modifications, and gene expression levels. PLoS Genet. 2014;10: e1004663.","journal-title":"PLoS Genet"},{"key":"1216_CR76","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1002\/acn3.201","volume":"2","author":"LB Chibnik","year":"2015","unstructured":"Chibnik LB, et al. Alzheimer\u2019s loci: epigenetic associations and interaction with genetic factors. Ann Clin Transl Neurol. 2015;2:636\u201347.","journal-title":"Ann Clin Transl Neurol"},{"key":"1216_CR77","doi-asserted-by":"publisher","first-page":"111cm33","DOI":"10.1126\/scitranslmed.3002609","volume":"3","author":"R.A Sperling","year":"2011","unstructured":"Sperling R.A, Jack C.R. Jr, Aisen P.S. Testing the right target and right drug at the right stage. Sci Transl Med. 2011;3:111cm33.","journal-title":"Sci Transl Med"},{"key":"1216_CR78","doi-asserted-by":"publisher","first-page":"17708","DOI":"10.1038\/s41598-022-21820-1","volume":"12","author":"MA Mortberg","year":"2022","unstructured":"Mortberg MA, Vallabh SM, Minikel EV. Disease stages and therapeutic hypotheses in two decades of neurodegenerative disease clinical trials. Sci Rep. 2022;12:17708.","journal-title":"Sci Rep"},{"key":"1216_CR79","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.gene.2009.11.006","volume":"451","author":"Y Wang","year":"2010","unstructured":"Wang Y, Gao L, Tse SW, Andreadis A. Heterogeneous nuclear ribonucleoprotein E3 modestly activates splicing of tau exon 10 via its proximal downstream intron, a hotspot for frontotemporal dementia mutations. Gene. 2010;451:23\u201331.","journal-title":"Gene"},{"key":"1216_CR80","doi-asserted-by":"crossref","unstructured":"Fisher E, Feng J. RNA splicing regulators play critical roles in neurogenesis. Wiley Interdiscip Rev RNA. 2022;13(6):e1728.","DOI":"10.1002\/wrna.1728"},{"key":"1216_CR81","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1186\/1471-2458-10-298","volume":"10","author":"IM Bensenor","year":"2010","unstructured":"Bensenor IM, Lotufo PA, Menezes PR, Scazufca M. Subclinical hyperthyroidism and dementia: the Sao Paulo Ageing & Health Study (SPAH). BMC Public Health. 2010;10:298.","journal-title":"BMC Public Health"},{"key":"1216_CR82","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1046\/j.1365-2265.2000.01146.x","volume":"53","author":"S Kalmijn","year":"2000","unstructured":"Kalmijn S, et al. Subclinical hyperthyroidism and the risk of dementia. The Rotterdam study Clin Endocrinol (Oxf). 2000;53:733\u20137.","journal-title":"The Rotterdam study Clin Endocrinol (Oxf)"},{"key":"1216_CR83","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1212\/01.WNL.0000128134.84230.9F","volume":"62","author":"LA van Osch","year":"2004","unstructured":"van Osch LA, Hogervorst E, Combrinck M, Smith AD. Low thyroid-stimulating hormone as an independent risk factor for Alzheimer disease. Neurology. 2004;62:1967\u201371.","journal-title":"Neurology"},{"key":"1216_CR84","doi-asserted-by":"crossref","unstructured":"Tifoun N, et al. A High-Throughput Search for SFXN1 Physical Partners Led to the Identification of ATAD3, HSD10 and TIM50. Biology (Basel). 2022;11(9):1298.","DOI":"10.3390\/biology11091298"},{"key":"1216_CR85","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1021\/acschemneuro.8b00194","volume":"9","author":"L Du","year":"2018","unstructured":"Du L, et al. Increased Iron Deposition on Brain Quantitative Susceptibility Mapping Correlates with Decreased Cognitive Function in Alzheimer\u2019s Disease. ACS Chem Neurosci. 2018;9:1849\u201357.","journal-title":"ACS Chem Neurosci"},{"key":"1216_CR86","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3389\/fnagi.2017.00081","volume":"9","author":"Y Sun","year":"2017","unstructured":"Sun Y, et al. Characterizing Brain Iron Deposition in Patients with Subcortical Vascular Mild Cognitive Impairment Using Quantitative Susceptibility Mapping: A Potential Biomarker. Front Aging Neurosci. 2017;9:81.","journal-title":"Front Aging Neurosci"},{"key":"1216_CR87","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/jmri.28043","volume":"56","author":"Z Qin","year":"2022","unstructured":"Qin Z, et al. Quantitative Susceptibility Mapping of Brain Iron Relating to Cognitive Impairment in Hypertension. J Magn Reson Imaging. 2022;56:508\u201315.","journal-title":"J Magn Reson Imaging"},{"key":"1216_CR88","doi-asserted-by":"crossref","unstructured":"Hogan R, et al. The Role of BMI1 in Late-Onset Sporadic Alzheimer\u2019s Disease. Genes (Basel). 2020;11(7):825.","DOI":"10.3390\/genes11070825"},{"key":"1216_CR89","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1016\/j.celrep.2018.04.097","volume":"23","author":"A Flamier","year":"2018","unstructured":"Flamier A, et al. Modeling Late-Onset Sporadic Alzheimer\u2019s Disease through BMI1 Deficiency. Cell Rep. 2018;23:2653\u201366.","journal-title":"Cell Rep"},{"key":"1216_CR90","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s12974-019-1545-x","volume":"16","author":"AB DePaula-Silva","year":"2019","unstructured":"DePaula-Silva AB, et al. Differential transcriptional profiles identify microglial- and macrophage-specific gene markers expressed during virus-induced neuroinflammation. J Neuroinflammation. 2019;16:152.","journal-title":"J Neuroinflammation"},{"key":"1216_CR91","doi-asserted-by":"publisher","first-page":"R806","DOI":"10.1016\/j.cub.2016.07.060","volume":"26","author":"C Duran-Aniotz","year":"2016","unstructured":"Duran-Aniotz C, Hetz C. Glucose Metabolism: A Sweet Relief of Alzheimer\u2019s Disease. Curr Biol. 2016;26:R806\u20139.","journal-title":"Curr Biol"},{"key":"1216_CR92","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13195-022-00996-8","volume":"14","author":"A Gonzalez","year":"2022","unstructured":"Gonzalez A, Calfio C, Churruca M, Maccioni RB. Glucose metabolism and AD: evidence for a potential diabetes type 3. Alzheimers Res Ther. 2022;14:56.","journal-title":"Alzheimers Res Ther"},{"key":"1216_CR93","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1093\/eurheartj\/ehu198","volume":"35","author":"CH Nolte","year":"2014","unstructured":"Nolte CH, Endres M. The heart of the matter: a link between troponin and dementia? Eur Heart J. 2014;35:1779\u201381.","journal-title":"Eur Heart J"},{"key":"1216_CR94","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1749-6632.2012.06482.x","volume":"1254","author":"JC Kovacic","year":"2012","unstructured":"Kovacic JC, Castellano JM, Fuster V. The links between complex coronary disease, cerebrovascular disease, and degenerative brain disease. Ann N Y Acad Sci. 2012;1254:99\u2013105.","journal-title":"Ann N Y Acad Sci"},{"key":"1216_CR95","doi-asserted-by":"publisher","first-page":"700","DOI":"10.2741\/e411","volume":"4","author":"E Emanuele","year":"2012","unstructured":"Emanuele E, Martinelli V, Abbiati V, Ricevuti G. Linking atherosclerosis to Alzheimer\u2019s disease: focus on biomarkers. Front Biosci (Elite Ed). 2012;4:700\u201310.","journal-title":"Front Biosci (Elite Ed)"},{"key":"1216_CR96","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1747-4949.2011.00731.x","volume":"7","author":"R Sahathevan","year":"2012","unstructured":"Sahathevan R, Brodtmann A, Donnan GA. Dementia, stroke, and vascular risk factors; a review. Int J Stroke. 2012;7:61\u201373.","journal-title":"Int J Stroke"},{"key":"1216_CR97","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1093\/eurheartj\/ehu124","volume":"35","author":"AL Schneider","year":"2014","unstructured":"Schneider AL, et al. High-sensitivity cardiac troponin T and cognitive function and dementia risk: the atherosclerosis risk in communities study. Eur Heart J. 2014;35:1817\u201324.","journal-title":"Eur Heart J"},{"key":"1216_CR98","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/j.bbamcr.2018.07.018","volume":"1865","author":"BC Tong","year":"2018","unstructured":"Tong BC, Wu AJ, Li M, Cheung KH. Calcium signaling in Alzheimer\u2019s disease & therapies. Biochim Biophys Acta Mol Cell Res. 2018;1865:1745\u201360.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"1216_CR99","doi-asserted-by":"crossref","unstructured":"Chami M. Calcium Signalling in Alzheimer\u2019s Disease: From Pathophysiological Regulation to Therapeutic Approaches. Cells. 2021;10(1):140.","DOI":"10.3390\/cells10010140"},{"key":"1216_CR100","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.neulet.2007.03.005","volume":"418","author":"M Raza","year":"2007","unstructured":"Raza M, et al. Aging is associated with elevated intracellular calcium levels and altered calcium homeostatic mechanisms in hippocampal neurons. Neurosci Lett. 2007;418:77\u201381.","journal-title":"Neurosci Lett"},{"key":"1216_CR101","doi-asserted-by":"publisher","first-page":"7905","DOI":"10.1523\/JNEUROSCI.5457-12.2013","volume":"33","author":"MM Oh","year":"2013","unstructured":"Oh MM, Oliveira FA, Waters J, Disterhoft JF. Altered calcium metabolism in aging CA1 hippocampal pyramidal neurons. J Neurosci. 2013;33:7905\u201311.","journal-title":"J Neurosci"},{"key":"1216_CR102","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1126\/science.1074069","volume":"298","author":"DJ Selkoe","year":"2002","unstructured":"Selkoe DJ. Alzheimer\u2019s disease is a synaptic failure. Science. 2002;298:789\u201391.","journal-title":"Science"},{"key":"1216_CR103","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/0022-510X(87)90057-8","volume":"78","author":"CA Davies","year":"1987","unstructured":"Davies CA, Mann DM, Sumpter PQ, Yates PO. A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer\u2019s disease. J Neurol Sci. 1987;78:151\u201364.","journal-title":"J Neurol Sci"},{"key":"1216_CR104","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.brainresrev.2011.01.003","volume":"67","author":"P Penzes","year":"2011","unstructured":"Penzes P, Vanleeuwen JE. Impaired regulation of synaptic actin cytoskeleton in Alzheimer\u2019s disease. Brain Res Rev. 2011;67:184\u201392.","journal-title":"Brain Res Rev"},{"key":"1216_CR105","doi-asserted-by":"publisher","first-page":"9171","DOI":"10.1523\/JNEUROSCI.3040-05.2005","volume":"25","author":"Q Ding","year":"2005","unstructured":"Ding Q, Markesbery WR, Chen Q, Li F, Keller JN. Ribosome dysfunction is an early event in Alzheimer\u2019s disease. J Neurosci. 2005;25:9171\u20135.","journal-title":"J Neurosci"},{"key":"1216_CR106","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/bpa.12335","volume":"26","author":"K Hernandez-Ortega","year":"2016","unstructured":"Hernandez-Ortega K, Garcia-Esparcia P, Gil L, Lucas JJ, Ferrer I. Altered machinery of protein synthesis in Alzheimer\u2019s: from the nucleolus to the ribosome. Brain Pathol. 2016;26:593\u2013605.","journal-title":"Brain Pathol"},{"key":"1216_CR107","first-page":"135","volume":"161","author":"M Watanabe","year":"2017","unstructured":"Watanabe M, Hatakeyama S. TRIM proteins and diseases. J Biochem. 2017;161:135\u201344.","journal-title":"J Biochem"},{"key":"1216_CR108","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.220098","volume":"12","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Afolabi LO, Wan X, Shim JS, Chen L. TRIM family proteins: roles in proteostasis and neurodegenerative diseases. Open Biol. 2022;12: 220098.","journal-title":"Open Biol"},{"key":"1216_CR109","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.jalz.2016.02.009","volume":"12","author":"L Yu","year":"2016","unstructured":"Yu L, et al. Methylation profiles in peripheral blood CD4+ lymphocytes versus brain: the relation to Alzheimer\u2019s disease pathology. Alzheimers Dement. 2016;12:942\u201351.","journal-title":"Alzheimers Dement"},{"key":"1216_CR110","doi-asserted-by":"publisher","first-page":"5620","DOI":"10.1038\/s41467-022-33394-7","volume":"13","author":"G Shireby","year":"2022","unstructured":"Shireby G, et al. DNA methylation signatures of Alzheimer\u2019s disease neuropathology in the cortex are primarily driven by variation in non-neuronal cell-types. Nat Commun. 2022;13:5620.","journal-title":"Nat Commun"},{"key":"1216_CR111","doi-asserted-by":"crossref","unstructured":"Silva TC, et al. Distinct sex-specific DNA methylation differences in Alzheimer\u2019s disease. Alzheimers Res Ther. 2022;14:133.","DOI":"10.1186\/s13195-022-01070-z"},{"key":"1216_CR112","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.jalz.2013.09.003","volume":"10","author":"J Nettiksimmons","year":"2014","unstructured":"Nettiksimmons J, DeCarli C, Landau S, Beckett L, Alzheimer\u2019s Disease Neuroimaging, I. Biological heterogeneity in ADNI amnestic mild cognitive impairment. Alzheimers Dement. 2014;10:511-521 e1.","journal-title":"Alzheimers Dement"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-023-01216-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-023-01216-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-023-01216-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T09:03:38Z","timestamp":1681117418000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-023-01216-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,10]]},"references-count":112,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1216"],"URL":"https:\/\/doi.org\/10.1186\/s13195-023-01216-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2391364\/v1","asserted-by":"object"}]},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,10]]},"assertion":[{"value":"18 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study procedures were approved by the institutional review boards of all participating centers (\n                      \n                      ), and written informed consent was obtained from all participants or their authorized representatives. The study was conducted in accordance with the Declaration of Helsinki and all study participants provided written informed consent for data collection. All work complied with ethical regulations for working with human participants. Ethics approval was obtained from the institutional review boards of each institution involved: Oregon Health and Science University; University of Southern California; University of California\u2014San Diego; University of Michigan; Mayo Clinic, Rochester; Baylor College of Medicine; Columbia University Medical Center; Washington University, St. Louis; University of Alabama at Birmingham; Mount Sinai School of Medicine; Rush University Medical Center; Wien Center; Johns Hopkins University; New York University; Duke University Medical Center; University of Pennsylvania; University of Kentucky; University of Pittsburgh; University of Rochester Medical Center; University of California, Irvine; University of Texas Southwestern Medical School; Emory University; University of Kansas, Medical Center; University of California, Los Angeles; Mayo Clinic, Jacksonville; Indiana University; Yale University School of Medicine; McGill University, Montreal-Jewish General Hospital; Sunnybrook Health Sciences, Ontario; U.B.C. Clinic for AD & Related Disorders; Cognitive Neurology\u2014St. Joseph\u2019s, Ontario; Cleveland Clinic Lou Ruvo Center for Brain Health; Northwestern University; Premiere Research Inst (Palm Beach Neurology); Georgetown University Medical Center; Brigham and Women\u2019s Hospital; Stanford University; Banner Sun Health Research Institute; Boston University; Howard University; Case Western Reserve University; University of California, Davis\u2014Sacramento; Neurological Care of CNY; Parkwood Hospital; University of Wisconsin; University of California, Irvine\u2014BIC; Banner Alzheimer\u2019s Institute; Dent Neurologic Institute; Ohio State University; Albany Medical College; Hartford Hospital, Olin Neuropsychiatry Research Center; Dartmouth-Hitchcock Medical Center; Wake Forest University Health Sciences; Rhode Island Hospital; Butler Hospital; UC San Francisco; Medical University South Carolina; St. Joseph\u2019s Health Care Nathan Kline Institute; University of Iowa College of Medicine; Cornell University and University of South Florida: USF Health Byrd Alzheimer\u2019s Institute. The investigators within the ADNI contributed to the design and implementation of the ADNI and\/or provided data but did not participate in the analysis or writing of this report. A complete listing of ADNI investigators can be found online (\n                      \n                      ).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"78"}}